# Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

> **NCT01396070** · PHASE2 · COMPLETED · sponsor: **Youn Kim** · enrollment: 36 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma (NHL)
- Cutaneous Lymphoma
- Cutaneous T-cell Lymphoma (CTCL)
- Mycosis Fungoides
- Sezary Syndrome

## Interventions

- **DRUG:** Brentuximab vedotin

## Key facts

- **NCT ID:** NCT01396070
- **Lead sponsor:** Youn Kim
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2015-04
- **Final completion:** 2016-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01396070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01396070, "Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01396070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*